News - TIAP
FedDev Ontario Funding Support – Portfolio Investments
On October 9, 2020, the Honourable Mélanie Joly, then Minister of Economic Development and Official Languages and Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) announced a FedDev Ontario contribution of $6.5 million to Toronto Innovation Acceleration Partners. Read more here: https://bit.ly/3nBEXDR
Under this Agreement, TIAP has to date made the following investments in our portfolio startup companies:
Bitnobi - $15,000, April 1, 2019
Bright Angel Therapeutics - $30,000, August 2, 2019 and $70,000, December 23, 2020
Elarex (McMaster University) - ...
Read more
TIAP and Evotec Expand LAB150 Bridge Partnership to Include Amgen
TIAP announced today the significant expansion of its flagship LAB150 drug discovery and development program with the addition of Amgen as a strategic and financial partner. Read full press release: https://bwnews.pr/3D3DUXb
LAB150 was created in 2017 with Evotec as the first North American BRIDGEs program to accelerate the development of novel therapeutics from our Members. Today’s announcement not only provides pre-seed capital of US$14M to these emerging drug development projects but also significant expertise and mentorship to our local scientists and innovators from ...
Read more
Phase 2 clinical trial targeting diabetes
TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here.
Why this news is important:
Zucara has achieved the development milestones required to secure the remaining funds available from its previously announcedUS$21 million Series A Financing.
Zucara plans to file an investigational new drug (“IND”) application for a Phase 2 trial by year end, with initiation of first patient dosing expected in Q1 2023.
ZT-01 has the potential to become the first therapeutic designed ...
Read more
Highly Positive Results from PoC Phase 1b trial of ZT-01 – Type 1 Diabetes
Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important:
This trial confirms ZT-01’s mechanism of action in restoring glucagon release in patients with T1D.
First-in-class ZT-01, meaningfully restored glucagon release in nearly 90% of treated patients compared to placebo (p<0.0001). This therapy has the potential to become the first therapeutic to prevent hypoglycemia in people with insulin-dependent diabetes.
Positive results from this trial will enable Zucara to further evaluate ZT-01 in a multi-center Phase 2 ...
Read more
Phenotips Raises $2.5M in First Round of Financing
Our startup company, Phenotips (formerly Gene42), announced in September, 2021, that it raised C$2.5M in its first round of financing. TIAP was an early investor and most recently, in this round, participated with additional $100K through its FedDev program. This brings TIAP's total investment as of September 2021 to $300K. Read more about the financing round here.
Phenotips has developed the world’s first "Genomic Health Record,” which offers software to standardize and share genomic medicine workflows. It is now translated into 5 ...
Read more
Roadmap for an Integrated Life Sciences Ecosystem In Ontario
LSO - Life Sciences Ontario - prepared an in-depth and informative report on the importance of the life science sector in Ontario. TIAP was one of the endorsing organizations. The report was published in May 2021.
https://lifesciencesontario.ca/wp-content/uploads/2021/05/LSO-RoadMap-Final.pdf
Read more
Notch Therapeutics Raises $85M Series A Financing
TIAP portfolio company Notch Therapeutics has announced one of the largest Series A financing rounds in the history of Canadian biotech. We are proud to say that we were there from the start in 2017 when TIAP received the technology disclosure from Dr. Zuniga-Pflucker via our Member, Sunnybrook Health Sciences Centre, and then again when we teamed up with CCRM and Dr. Peter Zandstra of University of Toronto, another one of our Members. TIAP was an early seed investor and acknowledges ...
Read more
Webinar February 24, 2021: Adventures in Drug Hunting – Identify and Advance Your Drug-Like Molecule
On February 24, 2021 TIAP hosted a LAB150 webinar entitled Adventures in Drug Hunting: Identify and Advance Your Drug-Like Molecule.
Here is the full description of the webinar content:
In the second of three webinars in the LAB150 series, we turn to the initial stages of identifying and developing a therapeutic compound. This follows our previous discussion of target identification and validation.
Now that you have a validated therapeutic target, how do you go about discovering modulators of this target in an efficient and rational ...
Read more
TIAP & Amgen Co-funds transformative projects to support new venture development
December 8, 2020
TIAP announces co-funding of transformative projects with Amgen to support new venture development
Toronto Innovation Acceleration Partners (TIAP) is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto, University Health Network (UHN) and The Hospital for Sick Children (SickKids).
The TIAP-Amgen partnership, formalized in 2019, has an objective to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations ...
Read more